Vanda Pharmaceuticals Inc.
VNDA
$4.92
-$0.10-1.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.26M | 52.59M | 50.04M | 53.19M | 47.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.26M | 52.59M | 50.04M | 53.19M | 47.65M |
| Cost of Revenue | 2.95M | 2.74M | 3.52M | 2.59M | 2.55M |
| Gross Profit | 53.30M | 49.85M | 46.52M | 50.60M | 45.10M |
| SG&A Expenses | 60.27M | 64.62M | 50.08M | 39.28M | 37.57M |
| Depreciation & Amortization | 1.75M | 1.75M | 1.75M | 1.75M | 1.75M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.54M | 91.09M | 91.07M | 63.46M | 58.65M |
| Operating Income | -31.28M | -38.50M | -41.03M | -10.28M | -11.00M |
| Income Before Tax | -28.39M | -34.89M | -37.37M | -6.50M | -6.24M |
| Income Tax Expenses | -5.80M | -7.68M | -7.87M | -1.59M | -920.00K |
| Earnings from Continuing Operations | -22.59M | -27.21M | -29.49M | -4.91M | -5.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.59M | -27.21M | -29.49M | -4.91M | -5.32M |
| EBIT | -31.28M | -38.50M | -41.03M | -10.28M | -11.00M |
| EBITDA | -29.23M | -36.49M | -39.05M | -8.31M | -9.03M |
| EPS Basic | -0.38 | -0.46 | -0.50 | -0.08 | -0.09 |
| Normalized Basic EPS | -0.30 | -0.37 | -0.40 | -0.14 | -0.07 |
| EPS Diluted | -0.38 | -0.46 | -0.50 | -0.09 | -0.09 |
| Normalized Diluted EPS | -0.30 | -0.37 | -0.40 | -0.14 | -0.07 |
| Average Basic Shares Outstanding | 59.09M | 58.99M | 58.53M | 58.31M | 58.26M |
| Average Diluted Shares Outstanding | 59.09M | 58.99M | 58.53M | 58.31M | 58.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |